AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA (ANHL)

Clinical trials for AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA (ANHL) explained in plain language.

Never miss a new study

Get alerted when new AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA (ANHL) trials appear

Sign up with your email to follow new studies for AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA (ANHL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

New antibody therapy tested for Tough-to-Treat blood cancers

Disease control Ongoing

This trial is testing a new antibody drug called epcoritamab in people with B-cell lymphoma that has come back or stopped responding to standard treatments. The main goals are to find the safest and most effective dose, understand the side effects, and see how well the drug works…

Matched conditions: AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA (ANHL)

Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control

Last updated Mar 30, 2026 14:32 UTC

AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA (ANHL)

Get alerted when new AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA (ANHL) trials appear

New antibody therapy tested for Tough-to-Treat blood cancers